Kura Oncology, Inc. (KURA) Stock Rating Upgraded by Zacks Investment Research
Kura Oncology, Inc. (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The brokerage presently has a $15.00 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 15.83% from the company’s previous close.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other brokerages have also recently issued reports on KURA. Citigroup Inc. set a $13.00 price objective on shares of Kura Oncology and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $16.00 target price on shares of Kura Oncology in a research note on Wednesday, June 28th. Cowen and Company assumed coverage on shares of Kura Oncology in a research note on Thursday, September 7th. They set an “outperform” rating for the company. Leerink Swann reaffirmed an “outperform” rating and set a $18.00 target price (up from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Finally, ValuEngine raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $15.60.
Kura Oncology (KURA) traded down 2.26% on Friday, hitting $12.95. 1,610,746 shares of the stock were exchanged. The firm’s market cap is $258.84 million. Kura Oncology has a 12 month low of $4.00 and a 12 month high of $13.80. The company has a 50-day moving average of $8.37 and a 200 day moving average of $8.90.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.03. Equities research analysts expect that Kura Oncology will post ($1.53) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/16/kura-oncology-inc-kura-stock-rating-upgraded-by-zacks-investment-research-2.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Oppenheimer & Co. Inc. grew its stake in Kura Oncology by 14.7% during the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after acquiring an additional 1,600 shares in the last quarter. Nationwide Fund Advisors grew its stake in Kura Oncology by 66.2% during the second quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock valued at $240,000 after acquiring an additional 10,258 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in Kura Oncology during the second quarter valued at $102,000. Segantii Capital Management Ltd purchased a new position in Kura Oncology during the first quarter valued at $120,000. Finally, Rhumbline Advisers purchased a new position in Kura Oncology during the second quarter valued at $131,000. 39.07% of the stock is owned by institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.